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Abstract
Background: Oral cancer survival rates increase significantly when it is detected and treated early. Unfortunately, clinicians
now lack tests which easily and reliably distinguish pre-malignant oral lesions from those already transitioned to
malignancy. A test for proteins, ones found in non-invasively-collected whole saliva and whose abundances distinguish
these lesion types, would meet this critical need.
Methodology/Principal Findings: To discover such proteins, in a first-of-its-kind study we used advanced mass
spectrometry-based quantitative proteomics analysis of the pooled soluble fraction of whole saliva from four subjects with
pre-malignant lesions and four with malignant lesions. We prioritized candidate biomarkers via bioinformatics and validated
selected proteins by western blotting. Bioinformatic analysis of differentially abundant proteins and initial western blotting
revealed increased abundance of myosin and actin in patients with malignant lesions. We validated those results by
additional western blotting of individual whole saliva samples from twelve other subjects with pre-malignant oral lesions
and twelve with malignant oral lesions. Sensitivity/specificity values for distinguishing between different lesion types were
100%/75% (p=0.002) for actin, and 67%/83% (p,0.00001) for myosin in soluble saliva. Exfoliated epithelial cells from
subjects’ saliva also showed increased myosin and actin abundance in those with malignant lesions, linking our
observations in soluble saliva to abundance differences between pre-malignant and malignant cells.
Conclusions/Significance: Salivary actin and myosin abundances distinguish oral lesion types with sensitivity and specificity
rivaling other non-invasive oral cancer tests. Our findings provide a promising starting point for the development of non-
invasive and inexpensive salivary tests to reliably detect oral cancer early.
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Introduction
Oral cancer develops in stages, transitioning from a normal oral
epithelium, to a pre-malignant, dysplastic oral lesion, to a
malignant lesion, most commonly in the form of oral squamous
cell carcinoma (OSCC). For those who develop OSCC, the overall
5- year survival rate is approximately 50%, unchanged over the
last 30 years[1]. For those where malignancy is detected early,
soon after transitioning from pre-malignancy, treatment is more
effective, and consequently the survival rate increases to about
80%[2]. Clearly, the ability to distinguish between pre-malignant
and malignant oral lesions is crucial[1,3].
Unfortunately, pre-malignant and malignant lesion types cannot
be distinguished simply by visual inspection; instead invasive tests
are used. The current gold standard for characterizing lesions,
histological analysis of tissue biopsies[3], has several disadvantages:
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11148expert clinicians are required to collect the samples and interpret
results, incurring relatively high costs; inaccuracies in diagnosis
due to difficulties sampling tissue which may have multiple
dysplastic foci; and patient discomfort with the procedure.
Together these disadvantages limit the accuracy of diagnosis, the
frequency of patient testing, and consequently the ability to detect
oral cancer early by tissue biopsy.
Non-invasive, inexpensive and accurate tests, ones which foster
early and frequent screening, would, if available, transform the
early detection of oral cancer. Whole saliva collection is non-
invasive, providing inexpensive collection of ample amounts of
sample for analysis in an on-demand manner[4,5]. Protein
biomarkers in whole saliva could fulfill this need if their abundance
levels distinguish patients with pre-malignant oral lesions from
those with malignant lesions. Whole saliva’s direct interaction with
the oral lesion points to a high probability of it containing lesion-
associated proteins diagnostic of its pre-malignant or malignant
status. Ideally, protein biomarkers from saliva would be detected
inexpensively and easily using point-of-care devices, either in the
clinic or even at home.
So far there are only a few proteomic studies relevant to
developing such protein-based tests. Analyzing biopsied tissues,
two such studies were recently published by Siu and colleagues,
resulting in the identification of several promising biomarkers.
One study compared protein abundance levels between healthy
tissue and pre-malignant dysplastic tissue[6]; the other compared
protein abundance levels between healthy tissue and malignant
tissue[7]. Another study identified proteins whose abundance
differed between healthy and malignant oral tissue, and then
validated, via immunohistochemistry, the ability of some of these
proteins to distinguish pre-malignant dysplastic lesions from
malignant lesions[8]. However, the potential biomarker proteins
were not validated in saliva, where they would have the most value
for clinical assays. Another recent study in saliva[9] used
proteomics to discover proteins whose abundance levels distin-
guished subjects with no oral lesions from those with malignant
lesions.
Sadly, given their great potential for discovering promising
biomarkers for early detection of oral cancer, no proteomic studies
in saliva have been undertaken comparing subjects with pre-
malignant and malignant lesions. Despite the urgent need for such
studies, these are not easily undertaken. A main reason for this is
the difficulty in collecting even modest numbers of samples from
subjects with pre-malignant oral lesions, as most clinicians see
these subjects sporadically and lack coordinated infrastructure for
sample collection and analysis.
In this first-of-its-kind study, we have overcome this difficulty,
collecting saliva samples from subjects with pre-malignant oral
lesions and using advanced mass spectrometry-based proteomics
to discover salivary protein abundance differences between these
subjects and those with malignant oral lesions. Via bioinformatic
analysis and biochemical validations, we have identified myosin
and actin as promising salivary biomarkers capable of distinguish-
ing between subjects with pre-malignant and malignant lesions.
Our results provide a basis for the potential development of a
salivary-based test for the early detection of oral cancer.
Materials and Methods
Ethics statement
The study was done with informed written consent of all sample
donors using a human subjects protocol approved by the
Institutional Review Board at the University of Minnesota (IRB
study number 0001M34501).
Clinical whole saliva collection protocol from subjects
Unstimulated whole saliva was collected from two groups:
subjects with pre-malignant dysplastic lesions diagnosed by scalpel
biopsy and histology, and subjects with invasive malignant lesions,
diagnosed as primary OSCC by scalpel biopsy and histology. All
OSCC patients were non-metastatic, and had either T1 or T2
stage tumors. Subjects with either lesion type (pre-malignant or
malignant) had not undergone any treatment or surgery (including
tissue biopsy) at the lesion site prior to saliva collection.
Unstimulated whole saliva was obtained using a standard,
controlled protocol[10] by first having each subject swallow and
then expectorate continuously into a 50-ml sterile, polypropylene
conical tube for a period of 5 min. This resulted in about 2–5 mL
of total saliva from each subject. Following collection, the samples
were immediately placed on ice and stored at 270uC until further
processing. Subjects included in the study were free of confound-
ing conditions: periodontal disease, auto-immune disease, a prior
history of diseases of the oral mucosa, or current use of potentially
confounding medications.
Whole saliva sample preparation
For proteomic discovery studies and western blot validation
studies, samples from subjects falling in the two groups were
prepared identically. Whole saliva was centrifuged at 3000 x g at
4uC, the supernatant containing the soluble fraction of saliva
proteins removed, and the cell pellets washed with PBS and lysed
to obtain cellular proteins, as previously described[11]. Total
protein was quantified using the BCA assay (Thermo Pierce).
Protein Digestion, iTRAQ labeling and peptide
fractionation
For proteomic discovery experiments, 200 mg of denatured and
reduced protein from the soluble portion of saliva from each of four
subjects with pre-malignant lesions was pooled together; likewise,
200 mg of denatured and reduced protein from the soluble portion
of saliva from each of four subjects with pre-malignant lesions was
pooled together. Each separate sample pool was digested overnight
with trypsin as previously described[11,12]. Resulting peptides were
concentrated and purified via mixed-mode cation exchange solid-
phase extraction columns (Waters). The resulting peptides from
each of the subjects were then combined and labeled with the
iTRAQ reagent[13] (Applied Biosystems, Foster City) following the
manufacturer’s procedure, labeling samples from subjects with pre-
malignant lesions with reagent 115 and samples from subjects with
malignant lesions with reagent 116. The iTRAQ labeled peptide
mixtures were combined and fractionated using a 3-step method
described previously combining preparative isoelectric focusing
(IEF), strong cation exchange (SCX) and reversed-phase micro-
capillary liquid chromatography[11].
Mass spectrometric analysis
Mass spectrometry was done using an LTQ linear ion trap mass
spectrometer (Thermo Finnigan, Inc) using Xcalibur version 2.0
operating software. In order to detect low mass reporter ions from
the iTRAQ reagent, the instrument was operated using pulsed Q
dissociation (PQD) mode. We have described in detail the
procedure used for PQD analysis of iTRAQ reagent labeled
peptides previously, as well as the HPLC and LTQ operating
conditions for tandem mass spectrometry (MS/MS) analysis[14].
Protein Identification and Quantification
MS/MS spectra were searched using SEQUEST(15) (Version
27, Thermo Finnigan, San Jose, CA) against a non-redundant
Oral Cancer Saliva Biomarkers
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matics Institute (ipi.HUMAN.v3.18.fasta, containing 62,000
entries) comprised of both the forward and reversed sequences,
using parameters as previously described[11]. Peptides matched to
MS/MS by SEQUEST were filtered using their expected
isoelectric points, based upon their fractionation by preparative
IEF, as we have described previously[11]. The estimated spectral
false positive rate for both the soluble and cellular proteins were
below 1%, based on matches to the reversed database[15]. In
order to report the minimum set of protein sequences in our
proteomic catalogue that adequately accounts for all matched
peptides we analyzed all matched peptide sequences for redundant
inclusion in multiple proteins in our sequence database. Proteins
identified from at least one non-redundant peptide sequence were
retained in our catalogue. For proteins identified from redundant
peptides, we retained those proteins in our catalogue only if the
redundant proteins matched to a closely related isoform of the
same protein in the database. Proteins identified from redundant
peptides that matched to different proteins entirely were removed.
Relative protein abundance ratios between the two subject groups
were calculated from iTRAQ reagent reporter ion intensities, using
an in-house developed automated software program, as we have
previously described[14]. Only proteins identified from two or more
MS/MS spectra matched to peptides were considered for quantita-
tive analysis. To account for any systematic errors biasing our relative
protein abundance ratios, each protein ratio was normalized by
calculating the median ratio across the entire set of proteins and
dividing each protein ratio by this median value. Normalization was
done by diving each ratio by the median ratio in the log2 scale:
normalized ratio =2
[log
2
(protein ratio) - log
2
(median ratio)].
To determine proteins showing significant abundance differ-
ences between the different subject groups, mean and standard
deviation for each ratio was calculated across all matched MS/MS
spectra, and used to determine proteins showing significant
differences in abundance between the two groups. Proteins with
abundance differences greater than one standard deviation from
the mean value were deemed to be significantly changing.
Bioinformatic analysis
Proteins from the soluble fraction of whole saliva showing
significant abundance differences between the two subject groups
were analyzed using Ingenuity Pathway Analysis (IPA) software
(Ingenuity Systems, Inc) were mapped to canonical pathways. For
each dataset analyzed, a corresponding control dataset was also
analyzed containing proteins not showing abundance differences
between the two stages of oral cancer development. A relative
abundance window centered at unity was used to generate a
random dataset of control proteins numbering the same as the
proteins showing differences in relative abundance. The signifi-
cance of the association between proteins within each dataset and
the canonical pathway was measured in two ways: 1) A ratio of the
number of molecules from the data set that map to the pathway
divided by the total number of molecules that map to the
canonical pathway is displayed. 2) Fisher’s exact test was used to
calculate a p-value determining the probability that the association
between the genes in the dataset and the canonical pathway is
explained by chance alone.
Western blot validation experiments
Commercial antibodies used for western blot validation
experiments were as follows (product numbers in parentheses):
myosin regulatory light chain, monoclonal antibody (Santa Cruz
Biotechnology, Inc., sc-48414), and actin, monoclonal anti-actin
Ab5 (BD Transduction Laboratories, 612657).
Thirty mg of protein from each individual subject analyzed in
validation experiments (12 individuals with pre-malignant lesions
and 12 with malignant lesions), along with thirty mg of control
protein from a control saliva pool, and molecular weight markers
was loaded in separate lanes and separated via SDS-PAGE on a
Bio-Rad minigel apparatus. The proteins were transferred to a
PVDF membrane and the membrane blocked with 1xPBS
containing 2.5 mg/ml BSA and 0.25% (v/v) Tween 20, followed
by incubation with the primary antibody, diluted in PBS at
concentrations suggested by the antibody manufacturer. After
washing, the membranes were incubated with secondary antibod-
ies conjugated to horseradish peroxidase (HRP).
For detection, membrane-bound proteins recognized by the
HRP conjugated secondary antibody were visualized by chemi-
lumenescence using the SuperSignal West Pico ECL Substrate
(Thermo Scientific). Developed films were imaged on a Bio-Rad
GS-700 Imaging Densitometer, and quantification performed on
background-subtracted bands with Molecular Analyst (v. 21)
Software. Densitometric values of all individual samples were
normalized against the signal from the common control. All blots
from soluble saliva were performed in triplicate, and the mean
values were used for statistical analyses.
Image files generated from densitometry detection were
imported to Adobe Photoshop version 9.0.2. Images were cropped
to show detected bands at correct, expected molecular weight
regions, and then converted to grayscale and subjected to
automated contrast adjustment using the default program settings.
Statistical analysis
For each candidate biomarker, the statistical difference between
the pre-malignant and malignant samples was compared using the
two-sample t-test with the Welch-Satterwaite method for samples
of different variances. If the difference is statistically significant at
the 5% level, an optimal cut-point is determined at which the
Youden’s Index is maximized[16]. Sensitivity (1-false negative
rate), the probability to correctly identify saliva collected from a
subject with a malignant lesion, and specificity (1-false positive
rate), the probability to correctly identify saliva collected from a
subject with a pre-malignant lesion, were calculated at that
optimal cut-point.
Results
Discovery of candidate biomarkers
For biomarker discovery, we employed a strategy implementing
several parts (Figure 1): experimental design, quantitative mass
spectrometry-based proteomics, bioinformatics, and validation.
Experimental details on the parts of our strategy are described in
Materials and Methods. We included for analysis saliva samples
collected from subjects at two different stages of oral cancer
development. These stages, detailed at the top of Figure 1, follow
the known course of development of oral cancer, transitioning
from a pre-malignant dysplastic lesion to a malignant lesion in the
form of OSCC[17]. Supplementary Table S1 contains
relevant information on all of the subjects whose saliva was
analyzed in our studies.
Our proteomics analysis identified a rich catalogue of 855 total
proteins complete with their relative abundance levels compared
between different stages of oral cancer development. Our
catalogue (Supplementary Table S2) was rigorously filtered
ensuring estimated spectral false positive rates below 1% and
minimal redundancy (see Materials and Methods for details). Of
the quantified proteins, 198 proteins showed significant abundance
Oral Cancer Saliva Biomarkers
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malignant oral lesions.
Bioinformatics for prioritizing and selecting candidate
biomarkers
Because validating proteins is time-consuming and expensive,
we could not possibly validate the almost 200 differentially
abundance proteins in our catalog. Instead, we sought to prioritize
them, and from those assigned highest priority select candidate
biomarkers proteins needing further validation. To that end, we
used the Ingenuity Pathway Analysis (IPA) tool to group into
functional pathways those proteins showing abundance differences
between the subjects with pre-malignant lesions and those with
malignant lesions. We hypothesized that such grouping would
reveal proteins within our catalogue from functional pathways
with possible ties to cancer progression, which we would assign
high priority. As a control, 198 randomly selected proteins
showing no significant abundance difference between the two
subject groups were also analyzed. Through this analysis pathways
associated with the transition from pre-malignancy to malignancy
would be significantly represented in the dataset of proteins
changing in abundance, but not in the dataset of control proteins.
Our analysis showed the three most significantly represented
pathways to be acute phase response, followed by actin
cytoskeleton signaling and tight junction signaling (Figure 2).
The inclusion of acute phase pathway proteins in our data might
be expected, given their role as responders to inflammation, a
condition that is central to oral cancer progression[6,10].
However, their activation within the oral cavity in response to a
variety of conditions other than cancer[18,19] limited their value
in prioritizing proteins for validation.
Conversely, the next two most significant categories, actin
cytoskeleton signaling and tight junction signaling, were assigned
high priority given their role in transforming cells from a pre-
malignant state to an invasive, malignant state[20,21]. Closer
inspection of those proteins revealed that myosin subunits were
highly represented, with all of these subunits showing increases in
abundance between the pre-malignant and malignant pooled
saliva samples from our proteomics data. We therefore selected
myosin as a candidate for further validation. Given the close
functional relationship of myosin with actin, and their joint role in
cell invasion in cancer progression[22], we expected that actin
might show a similar change in abundance. Inspection of our
catalogue revealed that beta actin, a main cytoskeletal actin
isoforms did increase by a modest amount (normalized abundance
ratio of 1.2), although it did not pass our criteria as being a
significant increase. Given this at least modest increase in
abundance along with its functional relationship with myosin, we
also selected actin for further validation as a candidate biomarker.
As a follow-up analysis, we also performed network analysis using
IPA on the differentially abundant proteins, and a network
containing actin and myosin subunits was among the most
significant returned (P=1610
235, Figure 2B), further supporting
the prevalence of actin and myosin proteins among those showing
abundance differences.
In addition to the myosin and actin, we also prioritized proteins
from our catalogue via manual inspection seeking to select other
candidate biomarker proteins warranting validation. Standing out
were 28 different keratin proteins identified and quantified in our
proteomics analysis, with the majority of these showing significant
increases in abundance between the pre-malignant and malignant
sample pools. Among the keratins, we selected keratin 19 for
Figure 1. Biomarker discovery strategy. The parts making up our integrated strategy are shown and described in the text.
doi:10.1371/journal.pone.0011148.g001
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OSCC tissues[23,24]. We also observed that catalase, recently
described as a saliva protein whose abundance change distin-
guishes healthy individuals from those with malignant oral
lesions[9], and the protein S100A7, recently described as a
biomarker distinguishing healthy and malignant oral tissue
Figure 2. Bioinformatic analysis of differentially abundant proteins. A. Significantly represented pathways of differentially abundant
proteins compared to control proteins (those showing no abundance differences) grouped by IPA. Pathways with bars rising above the significance
threshold are those containing sufficiently high numbers of proteins from our proteomic data such that they are deemed highly represented in a
statistically significant manner (See Materials and Methods for details on significance calculations). Numerical values in parentheses for each pathway
are the total number of proteins in the Ingenuity Pathway database mapping to that pathway. B. A significantly represented protein network
(P=1610
235) determined by IPA on differentially abundant soluble saliva proteins. Myosin subunits and actins are highly represented in this network
and shaded in black. Other differentially abundant proteins identified in our proteomics study are shaded in gray; proteins not identified in our
proteomics study are not shaded.
doi:10.1371/journal.pone.0011148.g002
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the pre-malignant and malignant sample pools in our proteomic
catalogue. We therefore selected both of these proteins for
validation.
Validation and statistical analysis of candidate
biomarkers
Candidate biomarkers (myosin, actin, S100A7, keratin 19 and
catalase) were validated via two rounds of quantitative western
blotting. Initially, we screened each protein in a small number of
independent samples from three pre-malignant and three
malignant subjects, seeking to confirm our proteomic results and
determine those showing the most significant and consistent
quantitative differences, which would then be selected for
validation in a larger number of patient samples. From this
screen, S100A7, catalase and keratin 19 did not show consistent
differences between pre-malignant and malignant subjects to merit
further validation (data not shown). Actin and myosin on the other
hand showed clear and consistent increases in their abundance
between samples from individuals with pre-malignant and
malignant oral lesions. We therefore selected these two proteins
for validation and statistical analysis in a larger number of patient
samples.
For actin and myosin validation, we analyzed by western blot
saliva samples collected from twelve subjects with pre-malignant
oral lesions and twelve subjects with malignant oral lesions (see
Supplementary Table S1 for information on subjects). None of
these subjects were used in our initial quantitative proteomics
analysis. In order to quantitatively compare western blotting
results measuring actin and myosin abundance levels in pre-
malignant or malignant subjects run on different gels, we used a
common reference sample on all blots, prepared by pooling saliva
from eleven healthy donors. For all western blots, the same
amount of protein from this reference sample and each subject was
loaded on the gel, and the signal intensity from either the actin or
myosin band from each subject normalized against the signal
intensity derived from the reference. To guard against potential
errors in sample loading and ensure the veracity of our findings,
blots for actin and myosin were performed in triplicate, and
normalized intensities for each protein averaged for each subject
across the three blots. Supplementary Figure S1 shows all the
images of all western blotting results for myosin and actin.
Figure 3 (panels A and B) shows a plot of the average
normalized intensity ratio from the twelve pre-malignant and
malignant subjects for actin and myosin, respectively. Both
proteins showed a clear increase in their salivary abundance in
subjects with malignant oral lesions compared to those with pre-
malignant lesions. Using the relative abundance levels compared
to the reference measured for each subject, sensitivity and
specificity values for distinguishing between subjects with pre-
malignant or malignant oral lesions were 100% and 75%,
respectively, for actin (p=0.002) and 67% and 83%, respectively,
for myosin (p,0.00001).
Figure 3. Summary of western blot validation results. Box plots of actin and myosin western blot data in soluble saliva (panels A and B, mean
of twelve samples tested in each subject group; the ratio for each sample being the mean of three technical replicates) and exfoliated cells in the
same saliva samples (panels C and D, mean of twelve samples tested in each subject group). Each plot displays the median (solid horizontal line
within each box), quartiles (area if each box), and range of the data (bars extending from each box). Western blots were performed for actin (A, C) and
myosin (B, D).
doi:10.1371/journal.pone.0011148.g003
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experimental evidence confirming the source of our observations
for actin and myosin in soluble saliva being their differential
expression in pre-malignant or malignant cells. Given that actin
and myosin are intracellular proteins, we assumed that the main
source of these proteins in saliva would be epithelial cells within
the oral cavity. We hypothesized that if our observed soluble saliva
abundance differences in these two proteins were truly a
consequence of the transformation of cells within oral lesions
from a pre-malignant state to a malignant state, their relative
abundance levels in exfoliated epithelial cells collected in saliva
from the same subjects would mirror those observed in the soluble
saliva. Our past results[11,25] have suggested that the exfoliated
cells present in saliva contain diagnostically valuable cells
emanating directly from the oral lesion supporting our reasoning
for their analysis to test our hypothesis.
To test our hypothesis, we performed a western blot for actin
and myosin on proteins from exfoliated cells contained in the
saliva of the same pre-malignant and malignant subjects used for
validations described above. Again, we normalized the intensities
of actin and myosin in each subject sample against a common
reference sample of proteins derived from exfoliated cells in a
saliva sample from pooled healthy donors. Supplementary
Figure S1 shows all the images of all western blotting results for
the cellular samples. Figure 3 (panels C and D) shows plots of
normalized actin and myosin western blot intensities averaged
across the pre-malignant and malignant subjects. Both proteins
showed overall increases in normalized abundance levels in
subjects with malignant oral lesions compared to those with pre-
malignant lesions. These findings support the assertion that our
observations for actin and myosin in soluble saliva are a direct
consequence of differences in their cellular abundances.
Discussion
In this study we sought to discover and validate protein
biomarkers of oral cancer in the soluble fraction of whole saliva.
Our study is the first to use advanced quantitative proteomics to
compare saliva collected from subjects with pre-malignant oral
lesions to saliva collected from subjects with malignant oral lesions.
One recent proteomic study[9] compared saliva from subjects with
no oral lesions to saliva from subjects with malignant oral lesions.
Although interesting, these results have limited relevance to
clinicians who are challenged mainly by distinguishing pre-
malignant from malignant oral lesions, rather than asymptomatic
healthy subjects with no lesions from those with malignancy. The
protein catalase provides an example of this limitation. Catalase
was significantly increased in abundance between healthy subjects
and those with malignant lesions in a recent study by Wong and
colleagues[9]. However, we found that catalase did not reliably
distinguish between subjects with pre-malignant lesions and those
with malignancy. Including subjects with pre-malignant oral
lesions allowed us to identify those candidate protein biomarkers
with the highest potential value for solving a critical problem in the
clinical management of oral cancer.
Owing to the uniqueness of our study, our protein catalogue
(Supplementary Table S2) may serve as a valuable guide to
others seeking to characterize salivary protein biomarkers of oral
cancer. Given the time and expense limitations, we were only able
to validate a relatively small number of the almost 200
differentially abundant proteins in our catalogue. It is very
possible that other promising biomarkers exist among this group
of differentially abundant proteins which we were unable to
include in validation studies. These may be identified in ongoing
studies by others, and when compared to our catalogue, bolster
confidence as candidates for further validation.
In our study, actin and myosin were the most promising
candidate saliva biomarkers identified. Both proteins displayed
increases in their abundance levels in soluble saliva from subjects
with malignant lesions, compared to those with pre-malignant
lesions. Additionally both proteins showed abundance increases in
the exfoliated cells from the saliva of the same subjects. These latter
findings provided critical evidence that the differences observed in
the soluble fraction of saliva are most likely a direct result of protein
differences occurring within the epithelial cells during the transition
from a pre-malignancy to malignancy. Importantly, we did not
observe an increase in the amount of exfoliated cells in malignant
salivas compared to pre-malignant salivas (data not shown),
suggesting that the observed increases in protein abundance are
due to increased actin and myosin expression within the exfoliated
cells with the onset of invasive oral malignancy, and not simply an
increase in the amount of cells in saliva.
In addition to our empirical evidence, previous descriptions of
the role of actin and myosin in the mechanism underlying the
transformation of pre-malignant epithelial cells to a malignant
state also support our findings. Actin and myosin are key
cytoskeletal proteins enabling cell motility and invasion, behavior
central to epithelial tumorigenesis[22,26]. Indeed, knockdown of
regulators of actin and myosin which causes their decreased
expression results in loss of cell migration and reduced invasion in
nasopharogeal carcinoma[27]. Consistent with our findings, actin
isoforms have been observed to be increased in abundance in in
vitro tumor cell migration studies[28], invasive basal cell carcino-
ma[29], cervical squamous cell carcinoma[30], esophageal
squamous cell carcinoma[31], as well as invasive OSCC[32].
Likewise, increases in myosin abundance have been reported in
proteomic studies of OSCC tissue[33], although other studies
seem to contradict these findings[34].
Our calculated sensitivity and specificity values respectively of
100% and 75% for actin, and 67% and 83% for myosin, are at
least comparable to published values of other non-invasive
detection methods currently used for distinguishing pre-malignant
and malignant oral lesions. A recent review by Lingen et al.
critiques the methods currently used by clinicians[3]. For example,
our results compare favorably to conventional oral examination by
an expert clinician, which, depending on the study cited, has
sensitivities as low as 60% and specificities as low as 75%[3,35].
Compared to this conventional method, a quantitative test based
on abundance levels of salivary actin and/or myosin could have
the added advantage of eliminating the subjective nature of the
clinical exam. Our results also compare well to the popular light-
based detection methods (e.g. ViziLite, VELscope) which, again
depending on the study, generally perform well, although
specificity values as low as 14% have been reported[36]. We did
evaluate the possibility of combining the relative abundance levels
of actin and myosin as a means for improving our ability to
distinguish pre-malignant and malignant lesions. However we
found that the combining the data did not significantly improve
our sensitivity and specificity.
In conclusion, via a proteomics study we have identified actin
and myosin as promising salivary biomarkers of oral cancer. More
rigorous determination in a larger number of samples of sensitivity
and specificity values for both proteins is necessary to better
understand their potential as biomarkers for widespread clinical
testing. However, our results illustrate their promise for develop-
ment into a simple and cost-effective test for oral cancer, with
potential implementation using emerging point-of-care nano-scale
devices for clinical diagnostics[37].
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